Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer
- 31 October 2006
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 103 (1), 145-150
- https://doi.org/10.1016/j.ygyno.2006.02.004
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer PatientsJournal of Clinical Oncology, 2005
- High frequency of human leucocyte antigen (HLA) A2 reflects a poorer prognosis in a group of advanced ovarian cancer patientsJournal of Clinical Oncology, 2005
- Correlation between HLA-A2 Gene Frequency, Latitude, Ovarian and Prostate Cancer Mortality RatesMedical Oncology, 2004
- A fresh look at tumor immunosurveillance and immunotherapyNature Immunology, 2001
- Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2Lung Cancer, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?Journal of Clinical Oncology, 1998
- Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemiaLeukemia, 1998
- Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaBritish Journal of Cancer, 1997
- Prolonged disease-free survival in bronchogenic carcinoma associated with HLA-Aw19 and HLA-B5:A two-year prospective studyCancer, 1977